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Abstract
Background: Systemic autoimmunity can be present years before clinical onset of rheumatoid arthritis (RA). Adaptive
immunity is initiated in lymphoid tissue where lymph node stromal cells (LNSCs) regulate immune responses through
their intimate connection with leucocytes. We postulate that malfunctioning of LNSCs creates a microenvironment in
which normal immune responses are not properly controlled, possibly leading to autoimmune disease. In this study
we established an experimental model for studying the functional capacities of human LNSCs during RA development.
Methods: Twenty-four patients with RA, 23 individuals positive for autoantibodies but without clinical disease (RA risk
group) and 14 seronegative healthy control subjects underwent ultrasound-guided inguinal lymph node (LN)
biopsy. Human LNSCs were isolated and expanded in vitro for functional analyses. In analogous co-cultures
consisting of LNSCs and peripheral blood mononuclear cells, αCD3/αCD28-induced T-cell proliferation was measured
using carboxyfluorescein diacetate succinimidyl ester dilution.
Results: Fibroblast-like cells expanded from the LN biopsy comprised of fibroblastic reticular cells (gp38+CD31−)
and double-negative (gp38−CD31−) cells. Cultured LNSCs stably expressed characteristic adhesion molecules and
cytokines. Basal expression of C-X-C motif chemokine ligand 12 (CXCL12) was lower in LNSCs from RA risk individuals
than in those from healthy control subjects. Key LN chemokines C-C motif chemokine ligand (CCL19), CCL21
and CXCL13 were induced in LNSCs upon stimulation with tumour necrosis factor-α and lymphotoxin α1β2, but to a
lesser extent in LNSCs from patients with RA. The effect of human LNSCs on T-cell proliferation was ratio-dependent
and altered in RA LNSCs.
Conclusions: Overall, we developed an experimental model to facilitate research on the role of LNSCs during
the earliest phases of RA. Using this innovative model, we show, for the first time to our knowledge, that the LN stromal
environment is changed during the earliest phases of RA, probably contributing to deregulated immune responses early
in disease pathogenesis.
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Background
The earliest stages of rheumatoid arthritis (RA) are char-
acterized by the presence of RA-specific autoantibodies
such as rheumatoid factor (RF) and anti-citrullinated
protein antibodies (ACPAs) years before the manifest-
ation of clinical disease [1]. In the Amsterdam health
care region, ACPA-positive individuals with arthralgia
have an approximately 50% chance of developing RA
within 3–4 years [2, 3]. Interestingly, during this at-risk
phase synovial inflammation as determined by immuno-
histochemistry seems absent, suggesting that infiltration
of the synovial tissue by inflammatory cells occurs in a
later stage [4, 5]. Because systemic autoimmunity seems
to precede synovial tissue inflammation, other, as yet
unidentified immune processes, possibly outside synovial
tissues, are altered and contribute to disease development.
To effectively mount an adaptive immune response,
secondary lymphoid tissues are essential. Animal models
have shown phenotypic changes in the cellular compart-
ment of peripheral lymph nodes (LNs) before the onset
of arthritis [6]. Recently, we detected altered frequencies
of B cells, T-cell subsets and innate lymphoid cell
subsets in LN biopsies of subjects with RA risk and
patients with early-stage RA when compared with
healthy control subjects [7–10], indicating that LN
activation was already present during the RA risk phase.
Studies in mouse models revealed that lymph node
stromal cells (LNSCs) play an important role in the
regulation of T- and B-cell responses [11, 12]. LNSCs
physically construct the LN, and through production of
chemokines and adhesion molecules, they guide immune
cells within the LN [13–15]. In addition, LNSCs produce
cytokines important for lymphocyte activation, diffe-
rentiation and survival [16]. In mouse models, LNSCs
have been found to induce peripheral T-cell tolerance by
direct antigen presentation and clonal deletion as well as
maintenance of regulatory T cells [17–19]. Furthermore,
during immune responses they are capable of sup-
pressing T-cell proliferation independently of antigens
[19–21]. Accordingly, LNSCs are key players in immunity
and tolerance. We hypothesise that malfunctioning of
LNSCs leads to a microenvironment where immune
responses are not properly controlled, which may lead
to the activation of (autoreactive) lymphocytes and
production of autoantibodies. LNSCs have been studied
mainly in animal models, because so far human LNSCs
have been obtained either from whole LNs removed
during surgery or from deceased individuals [22–24].
Isolating and sorting sufficient numbers of LNSCs
directly ex vivo is technically challenging [24]. We
therefore aimed to develop an experimental model to
allow research on human LNSCs during health and
RA and to lay the foundation for further research on
these immune-shaping cells.
Methods
Study subjects and lymph node biopsy sampling
Individuals with arthralgia and elevated immunoglobulin
M (IgM)-RF and/or ACPA levels but without any
evidence of arthritis upon examination were included
(individuals with RA risk phase C/D) [25]. Median
follow-up of individuals with RA risk was 20.3 months
(IQR 12.9–33.2), and none of the individuals with RA
risk developed arthritis during this period. In addition,
patients with RA with established disease based on fulfil-
ment of the American College of Rheumatology/European
League Against Rheumatism 2010 criteria [26] and as
assessed by the rheumatologist, as well as healthy control
subjects without any joint complaints and without
elevated IgM-RF and/or ACPA levels, were included. To
be eligible, the healthy control subjects could not have an
active viral infection or any history of autoimmunity
or malignancy and no present or previous use of dis-
ease-modifying anti-rheumatic drugs, biologics or other
experimental drugs. IgM-RF was measured using an
IgM-RF enzyme-linked immunosorbent assay (ELISA)
(upper limit of normal [ULN] 49 kU/L [kilo Unit/L];
HYCOR Biomedical, Garden Grove, CA, USA). ACPA
were measured using the CCPlus anti-cyclic citrulli-
nated peptide 2 ELISA (ULN 25 kAU/L [kilo arbitrary
Unit/L]; Euro Diagnostica, Malmö, Sweden). The
study was performed according to the principles of
the Declaration of Helsinki and approved by the insti-
tutional medical ethical review board of the Academic
Medical Centre, and all study subjects gave written
informed consent. All study subjects underwent an
ultrasound-guided inguinal LN needle core biopsy as
previously described [27]. Table 1 shows the demo-
graphics of the included subjects.
Lymph node stromal cell culture
After depletion of lymphocytes through a 70-μm cell
strainer (Corning, Landsmeer, the Nederlands), the
remaining stromal tissue of a freshly collected LN needle
core biopsy was plated on a 6-well culture dish (CELL-
STAR®; Greiner Bio-One/VWR, Alpen a/d Rijn, the
Nederlands) (passage 0; P0). Complete cell culture
medium was added. It consisted of DMEM, low glucose
(Thermo Fisher Scientific, Landsmeer, the Netherlands)
supplemented with 0.1% penicillin (Astellas Pharma Inc.,
Leiden, the Netherlands), 0.1% streptomycin, 0.05 mg/
ml gentamicin, 10 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) buffer, and 2 mM L-glu-
tamine (all from Thermo Fisher Scientific), as well as
10% FCS (GE Healthcare, Zeist, the Netherlands). Upon
reaching confluence of > 80% cells, were passaged to a
T75 tissue culture flask (P1) or into two T225 flasks
(P2; both Corning® Costar®; Corning). Before being har-
vested, cells were washed with sterile warm PBS
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(Fresenius Kabi, 's-Hertogenbosch, the Netherlands) and
incubated with 0.05% trypsin/5 mM ethylenediaminetetra-
acetic acid (Thermo Fisher Scientific) in PBS for 7 min at
37 °C. Subsequently, an equal amount of complete
medium was added, after which the cell suspension was
collected and centrifuged for 10 min at 1000 rpm at 4 °C.
Cells were resuspended in cold complete medium and
counted using trypan blue (Sigma-Aldrich, Zwijndrecht,
the Nederlands) in a BRAND® Bürker Türk chamber
(Sigma-Aldrich). Human LNSCs (passages 4 to 8) were
seeded in a 24-well plate (30,000 cells/well) and stimulated
with tumour necrosis factor-α (TNF-α) (5 ng/ml; Life
Technologies, Landsmeer, the Nederlands) plus lympho-
toxin α1β2 (50 ng/ml; R&D Systems, Abingdon, UK).
Flow cytometric analysis
Human LNSCs (passages 3 to 6) were cultured in a
6-well culture dish (100,000 cells/well). To harvest adherent
cells, 1 ml of TrypLE™ Select reagent (Thermo Fisher
Scientific) was added for 10 min at 37 °C. Subsequently,
cells were washed in protein blocking agent (PBA) buffer
(PBS containing 0.01% NaN3 and 0.5% bovine serum
albumin [Sigma-Aldrich]) and stained for 30 min at room
temperature protected from light using the following
directly labelled antibodies: CD45 fluorescein isothiocyanate
(FITC) (clone HI30; BD Diagnostics, Vianen, the
Netherlands), podoplanin Alexa Fluor 647 (clone NC-08;
BioLegend, London, UK), CD31 allophycocyanin
(APC)-eFluor 780 (clone WM-59; eBioscience, Vienna,
Austria), human leucocyte antigen A, B, C phycoerythrin-
cyanine 7 (PE-Cy7, clone G46–2.6; BioLegend), or corre-
sponding isotype controls. To examine the expression of
podoplanin on LNSCs cultured over different passages,
cells were stained for 1 h on ice with unconjugated anti-
human podoplanin (clone NZ-1; AngioBio, Huissen, the
Nederlands), washed, and subsequently incubated with
polyclonal goat anti-rat IgG Alexa Fluor 647 (Thermo
Fisher Scientific). Cells were washed in PBA and measured
using a FACSCanto II flow cytometer (BD Biosci-
ences, Vianen, the Nederlands). Data were analysed using
FlowJo software (FlowJo, Ashland, OR, USA).
Co-cultures containing LNSCs and PBMCs and T-cell
proliferation assay
LNSCs (passages 4 to 8) in amounts of 25,000, 10,000,
5000 or 1250 were seeded in duplicates in a 96-well flat-
bottomed plate and allowed to rest overnight in DMEM
complete culture medium. Subsequently, LNSCs were
Table 1 Demographic data of study subjects
Healthy control subjects (n = 14) Individuals with RA risk (n = 23) Patients with RA (n = 24)
Female sex, n (%) 9 (64) 20 (87) 17 (70)
Median age, years, (IQR) 29 (26–37) 49 (35–57) 56 (44–61)
IgM-RF-positive, n (%) 0 (0) 10 (43) 20 (3–107)
IgM-RF level, kU/L, median (IQR) – 20 (3–107) 131 (31–309)
ACPA-positive, n (%) 0 (0) 13 (57) 18 (75)
Median ACPA level, kAU/L (IQR) – 43 (4–177) 115 (21–924)
IgM-RF and ACPA both positive, n (%) 0 (0) 0 (0) 14 (58)
Median DAS28, (IQR) – – 5 (1–10)c
Median ESR, mm/h (IQR) – 7 (2–10) 11 (5–27)b
Median CRP, mg/L (IQR) 0.5 (0.3–1.2)c 1.6 (0.9–3.2) 4.6 (1.4–13)d
Median TJC68 (IQR) 0 (0) 1.5 (0–4.5) 9 (4–20)e
Median SJC68 (IQR) 0 (0) 0 (0) 5 (1–10)d
Treatment, n (%) 9 (39)
Corticosteroids 6 (26)
NSAIDs 4 (17)f
DMARDs 5 (22)
Failed TNF inhibitor therapy 5 (22)
Abbreviations: RA Rheumatoid arthritis, IgM-RF immunoglobulin M rheumatoid factor, kU/L kilo Unit/L, ACPA anti-citrullinated protein antibodies, kAU/L kilo arbitrary
Unit, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TJC68 68-joint tender joint count, SJC68 68-joint swollen joint count, NSAID non-steroidal anti-
inflammatory drug, DMARD disease-modifying antirheumatic drug, DAS28 disease activity score in 28 joints, TNF tumour necrosis factor
a Levels missing from one individual
b Levels missing from two individuals
c Levels missing from six individuals
d Levels missing from seven individuals
e Levels missing from five individuals
f Treatment unknown for five individuals
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pre-treated with 50 ng/ml interferon-γ (IFN-γ)
(eBioscience) for 48 h or refreshed with DMEM complete
medium. Peripheral blood mononuclear cells (PBMCs)
that had previously been isolated from healthy donors by
using standard density gradient centrifugation and subse-
quently cryopreserved, were thawed and allowed to rest
overnight at 37 °C in RPMI 1640 medium supplemented
with 10% FCS (GE Healthcare), 0.1% penicillin (Astellas
Pharma), 0.1% streptomycin, 10 mM HEPES buffer and
2 mM L-glutamine (all from Life Technologies). Then,
PBMCs were washed and labelled with 2 μl of
carboxyfluorescein diacetate succinimidyl ester (CFDA-SE)
FITC (clone C1157; Life Technologies) in PBS for 8 min at
37 °C. After removing DMEM complete medium and
washing LNSCs once with warm PBS, 50,000 labelled
PBMCs in RPMI complete medium per 96-well chamber
were added to LNSCs, resulting in ratios of 1:2, 1:5, 1:10
and 1:40 LNSCs to PBMCs. Simultaneously, PBMCs were
stimulated with anti-CD3 (1:10,000, clone 1XE; Sanquin,
Amsterdam, the Netherlands) and anti-CD28 (0.25 μg/ml,
clone 15E8; Sanquin). Cultures were harvested 96 h later,
washed with PBA buffer and stained for 30 min at room
temperature protected from light using the following
directly labelled antibodies: CD45 V500 (clone HI30; BD
Biosciences), CD4 PE-Cy7 (clone SK3; eBioscience) and
CD8a APC-eFluor 780 (clone SK1; eBioscience). Cells were
washed in PBA and measured using the FACSCanto II flow
cytometer. Data were analysed using FlowJo software. This
methodology was set up by testing PBMCs isolated from
four different healthy donors, whereas for the subsequent
co-culture experiments, PBMCs from one healthy donor
were selected to enable direct comparison between LNSCs
from different donors.
qRT-PCR
Messenger RNA (mRNA) was isolated using the RNeasy
Mini Kit or the RNeasy Micro Kit (Qiagen, Venlo, the
Netherlands) according to the manufacturer’s instructions,
including a DNase step to remove genomic DNA.
Subsequently complementary DNA (cDNA) was prepared
using the RevertAid H Minus First Strand cDNA
Synthesis Kit (Thermo Fisher Scientific). qRT-PCR was
performed using either TaqMan® Universal PCR Master
Mix combined with TaqMan assays or SYBR® Green PCR
Master Mix (all from Thermo Fisher Scientific) combined
with primers made in-house (Thermo Fisher Scientific).
The TaqMan assays and primer sequences are described
in Additional file 1: Table S1. For detection, we used the
StepOnePlus™ Real-Time PCR System (Thermo Fisher
Scientific). Values for each gene were normalized to the
expression level of 18S ribosomal RNA. An arbitrary
calibrator sample was used for normalization. For calcu-
lating the relative quantity, the 2−ΔΔCt comparative cycle
threshold method was used for TaqMan assays, and a
standard curve method was applied for SYBR Green
assays.
Nitric oxide measurement
Nitric oxide (NO) was measured by evaluating the nitrite
content in culture media using modified Griess reagent
(G4410; Sigma-Aldrich) according to the manufacturer’s
instructions. The co-culture supernatant (100 μl) of
healthy individuals with RA risk and of patients with
RA was mixed with the same volume of Griess reagent
for 5 min, and absorbance was measured at 540 nm. A
standard curve with increasing concentrations of
sodium nitrite (NaNO2) was constructed in parallel and
used for quantitation.
Statistics
Data are presented as median with IQR or mean with
SD when normally distributed. Differences between
study groups were analysed using the Kruskal-Wallis test
followed by Dunn’s post hoc test or two-way analysis of
variance followed by Dunnett’s multiple comparisons
test, where appropriate. Prism software version 7.01
(GraphPad Software, La Jolla, CA, USA) was used for
statistical analysis. P values < 0.05 were considered
statistically significant.
Results
Phenotyping of human LNSCs
Owing to the small size of the obtained LN needle
biopsies, digestion and immediate sorting of LNSCs
did not yield sufficient numbers of LNSCs for direct
analyses. However, LNSCs were capable of growing
in vitro from freshly obtained inguinal LN biopsies.
Mainly fibroblast-like cells expanded easily, and in
some donors LNSCs showed network formation
(Fig. 1a). Expanded LNSCs often contained a mixed
morphology consisting of fibroblastic as well as more
roundish cells, which was unrelated to disease state.
Whereas most LNSCs needed approximately 1–3 weeks
to reach confluence between passages, LNSCs from a few
donors required longer or failed to grow (11 of 136
donors). Overall, this culture system enabled a relatively
easy, although slow, expansion of human LNSCs.
Expanded human LNSCs in culture (passages 3–6)
consisted primarily of a mixture of double-negative cells
(DN; CD45−podoplanin−CD31−) and fibroblastic reticular
cells (FRCs; CD45−podoplanin+CD31−) as reported
previously [24] (Fig. 1b and c). The variation of
podoplanin-expressing cells within cultured human
LNSCs was similar between donor groups (Fig. 1c).
Podoplanin expression showed some variation in and
between donors over consecutive passages, but without a
consistent trend towards loss or increase across passages
(Fig. 1d), which corresponds to continuous podoplanin
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expression reported previously in human lymphatic
endothelial cells [28]. Furthermore, the frequency of
podoplanin-positive cells did not correlate with any
clinical parameters, such as autoantibodies or age (data
not shown).
LNSCs of patients with RA are less capable of inducing
key LN chemokines CCL19 and CXCL13
The expression of characteristic LNSC-related genes
such as vascular cell adhesion molecule 1 (VCAM-1),
intercellular adhesion molecule 1 (ICAM-1), lymphotoxin-β
receptor (LTβR), interleukin (IL)-7, B-cell-activating fac-
tor (BAFF) and IL-6 in LNSCs (all from passage 2) was
highly variable but showed no significant differences be-
tween donor groups and also not when stratified for ACPA
status. Only C-X-C motif chemokine ligand 12 (CXCL12)
showed a significantly lower expression in LNSCs from in-
dividuals with RA risk compared with healthy control sub-
jects (P = 0.0155) (Fig. 2a). To investigate whether these
LNSC characteristics changed during culturing, we cultured
LNSCs over several passages. We detected no significant
changes in mRNA levels of IL-7, VCAM-1, ICAM-1 and
podoplanin between passages 0 and 12 (n= 18) (Additional
file 1: Figure S1). Furthermore, we found no correlation
between the expression of genes analysed under homeo-
static conditions in P2 LNSCs with clinical parameters
such as age or autoantibody titres. When correlated with
podoplanin mRNA levels at P2 measured in total LNSC
cultures, we detected solely a significant, although weak,
correlation with IL-7 mRNA (P ≤ 0.0001; Spearman’s r =
0.534) (Additional file 1: Figure S2).
As anticipated, mRNA levels of C-C motif chemokine
ligand 19 (CCL19), CCL21 and CXCL13 in LNSCs were
low or undetected in LNSCs under homeostatic conditions,
but stimulation with TNF-α plus lymphotoxin α1β2 rapidly
induced these key LN chemokines. TNF-α and
lymphotoxin α1β2, produced by lymphocytes, are key
factors in the cross-talk between LNSCs and lymphocytes
Fig. 1 Morphologic and phenotypic characterization of cultured human lymph node stromal cells (LNSCs). a Cells growing out of the biopsy
were mainly fibroblastic and formed dense networks. During growth, human LNSCs also started to branch and stretch or showed a more
roundish morphology. b Flow cytometric analysis based on the expression of CD45, podoplanin (gp38) and CD31. Cells in culture (passages 3 to 6
[P3–P6]) were double-negative (DN) cells and fibroblastic reticular cell (FRCs). Gating was based on isotype controls. Human leucocyte antigen A, B, C
(HLA-ABC) expression served as a positive control. Representative figures of 2 donors out of 25 experiments are shown. c Frequencies of FRCs (CD45
−CD31− podoplanin [gp38]+) measured by fluorescence-activated cell sorting as described in (b) (P3–P6; n = 25) in different donor groups.
d Follow-up of podoplanin (gp38) expression over different culture passages as measured by flow cytometry in a different cohort of 16 donors (healthy, n
= 5; rheumatoid arthritis [RA] risk, n= 5; and RA, n= 6). APC Allophycocyanin, Cy Cyanine, FSC Forward scatter, PE Phycoerythrin, SSC Side scatter
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and in regulation of LN organogenesis, homeostasis and
remodelling, and they are known to induce the expression
of these critical characteristic chemokines produced by
LNSCs [29–31] (Fig. 2b) (n = 5 per donor group; donor
characteristics listed in Table 2).
Of interest, CCL19 and CXCL13 levels were signifi-
cantly differentially induced between the donor groups
(P = 0.0018 for CCL19 and P = 0.0155 for CXCL13), with
lower induction observed in LNSCs obtained from
patients with RA. This stimulation also strongly induced
the expression of VCAM-1 and ICAM-1, and to a lesser
extent IL-7 and podoplanin (Additional file 1: Figure S3).
We found no correlation between the induction of these
chemokines after stimulation with clinical parameters
such as age or autoantibody titres. Moreover, all observed
inductions of chemokines and characteristic genes were
independent of basal podoplanin protein expression
measured by fluorescence-activated cell sorting, indicating
that human DN cells and FRCs share these common
characteristics. However, the induction of ICAM-1
mRNA correlated strongly with the induction of podoplanin
mRNA (Additional file 1: Figure S4).
The effect of human LNSCs on T-cell proliferation is
ratio-dependent and altered in RA LNSCs
Finally, we aimed to investigate the effect of human
LNSCs on T-cell proliferation. Therefore, we performed
a co-culture experiment using a fixed number of 50,000
activated (anti-CD3 and anti-CD28) allogeneic PBMCs
derived from one healthy donor together with increasing
numbers of LNSCs (passages 4 to 8) from the different
study groups (Fig. 3). This way we were able to compare
the impact of LNSCs on T-cell proliferation between
healthy donors, individuals with RA risk and patients
with RA. Donors (n = 5 per study group; donor charac-
teristics listed in Table 3) were age- and sex-matched.
All donors with RA risk were ACPA+/RF−, whereas
patients with RA were ACPA+RF− or double-positive.
Fig. 2 Expression of genes characteristic for lymph node stromal cells (LNSCs). a Expression of genes in LNSCs of passage 2 was assessed by qPCR and
compared between different donor groups (healthy, n = 14; individuals with rheumatoid arthritis [RA] risk, n = 23; patients with RA, n = 24).
Relative quantity (RQ) is displayed as median and IQR. Differences between donor groups were assessed by the Kruskal-Wallis test followed by Dunn’s
post hoc test. * P < 0.050. b Expression of lymphoid chemokines was assessed after stimulation with tumour necrosis factor-α (TNFα) and lym-
photoxin α1β2 for 4 h, 8 h, 24 h, 48 h and 72 h by qPCR in LNSCs (passages 4 to 8). Mean fold induction (FI) and SD of n = 5 per donor group
are shown. Donor characteristics are listed in Table 2. BAFF B-cell-activating factor, CCL C-C motif chemokine ligand, CXCL C-X-C motif chemo-
kine ligand, ICAM-1 Intercellular adhesion molecule 1, IL Interleukin, mRNA Messenger RNA, VCAM-1 Vascular cell adhesion molecule 1
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LNSCs in different ratios with unstimulated PBMCs
did not induce proliferation (data not shown). We observed
that LNSCs affected anti-CD3/28-induced T-cell pro-
liferation in a ratio-dependent manner. In an LNSC/
T-cell ratio of 1:2, a clear suppression of T-cell pro-
liferation was observed, reflected by a lower number
of divisions as measured by carboxyfluorescein succinimidyl
ester dilution (Fig. 3a, blue line). Using the 1:2 LNSC/T-cell
ratio, we found that LNSCs from healthy donors and
individuals with RA risk induced a significantly higher
number of CD4+ and CD8+ T cells that divided only once
and then stopped proliferating (Fig. 3b, red bars), when
compared with stimulated T cells in the absence of LNSCs.
Of interest, this block in T-cell division was slightly
diminished in co-cultures of T cells with RA LNSCs;
however, variability between donors was high. In contrast,
when T cells were cultured with LNSCs from healthy
control subjects in ratios of 1:5 and 1:10 (Fig. 3a, orange
and pink lines), we observed a stimulatory effect on T-cell
proliferation, as observed by a significantly lower
frequency of undivided T cells (Fig. 3b, black bars), when
compared with stimulated T cells in the absence of
LNSCs. Notably, this stimulatory effect when using
LNSC/T-cell ratios of 1:5 and 1:10 was less clear in co-
cultures with LNSCs from individuals with RA risk or
patients with RA.
NO production by LNSCs is similar between healthy
subjects, individuals with RA risk and patients with RA
We also incubated LNSCs for 48 h with IFN-γ prior to
co-culture with T cells. IFN-γ produced by activated
T cells is known to play a key role in triggering NO
production by LNSCs and therefore in increasing their
immunosuppressive potential [20, 32, 33]. We found that
pre-incubation with IFN-γ indeed slightly boosted the
inhibitory capacity of LNSCs (as observed in the 1:2
LNSC/T-cell ratio) for most of the donors tested, including
RA LNSCs (Fig. 3b). Measurement of NO in co-culture
supernatants revealed a significantly higher NO pro-
duction (P = 0.001) in the situation in which LNSCs
and T cells were mixed in a 1:2 ratio when compared with
the 1:40 ratio (Fig. 3c). However, this significant increase
was observed similarly in all donor groups, and IFN-γ
stimulation did not show an additional effect. This
indicates that the increase in NO was probably due to
a higher density of LNSCs and was not related to the
altered T-cell proliferation observed when co-cultured
with RA LNSCs.
Discussion
In this study we set up an experimental model using
human LNSCs to allow research on the role of the
human LN microenvironment during health and RA.
The in vitro expanded human LNSCs express key charac-
teristics as described earlier in mice [16, 34]. During
passaging these markers stay relatively stable, and their
expression and induction are largely independent of
podoplanin expression, the main marker for FRCs. The
frequency of podoplanin-positive cells varied during
culturing and between donors, but without any consistent
trend towards loss of increase over passages. This
variation was observed especially in those LNSC cultures
containing high percentages of both FRC and DN cells,
therefore probably reflecting a preferential outgrowth of
one subset over the other. Mouse studies have shown that
DN cells and FRCs resemble each other but have a
differential expression of adhesion molecules and IL-7,
which in mice are exclusively expressed in FRCs [16]. Our
study showed similarities, because basal IL-7 mRNA levels
correlated positively with basal podoplanin mRNA levels,
and ICAM-1 induction appeared to be co-regulated with
podoplanin induction as also observed in mice [34].
However, we also demonstrate that LNSC cultures
consisting of cells with low podoplanin expression can also
Table 2 Demographic data of study subjects used in tumour necrosis factor-α and lymphotoxin α1β2 stimulation experiments
Healthy control subjects (n = 5) Individuals with RA risk (n = 5) Patients with early RAa (n = 5)
Passages P4–P6 P5–P8 P6–P7
Female sex, n (%) 5 (100) 5 (100) 4 (80)
Median age, years (IQR) 28 (26–40) 51 (49–57) 35 (28–58)
IgM-RF-positive, n (%) 0 (0) 4 (80) 3 (60)
IgM-RF level, kU/L, median (IQR) – 3 (1–42) 6 (3–288)
ACPA-positive, n (%) 0 (0) 4 (80) 4 (80)
ACPA level, kAU/L, median (IQR) – 47 (16–343) 54 (22–1563)
IgM-RF and ACPA both positive, n (%) 0 (0) 0 (0) 2 (40)
DAS28, median (IQR) – – 3.9 (3–7)
CRP, mg/L, median (IQR) 0.4 (0.3–2.7) 3.2 (1.9–4.4) 3 (0.9–100.4)
Abbreviations: ACPA anti-citrullinated protein antibodies, kAU/L kilo arbitrary Unit/L, CRP C-reactive protein, DAS28 disease activity score in 28 joints, IgM-RF im-
munoglobulin M-rheumatoid factor, kU/L kilo Unit/L, RA rheumatoid arthritis
a Patients with early RA: naïve for disease-modifying anti-rheumatic drugs and biologics with a disease duration (defined by arthritis in any joint) less than 1 year
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express relatively high levels of IL-7. In addition, in human
LNSC cultures DN cells are relatively more abundant than
FRCs as described before [24]. Together, these findings
suggest a comparable role of DNs and FRCs in humans, al-
though additional studies using isolated LNSC subsets are
essential to prove this.
Interestingly, the expression of CXCL12, a B-cell
chemoattractant [35], was significantly lower in LNSCs
derived from individuals with RA risk than in healthy
control subjects. CXCL12+ stromal cells derived from
both bone marrow and tonsils (LN-like FRCs) of healthy
donors can attract malignant B cells and appear to
enhance the survival of follicular lymphoma B cells
compared with healthy B cells isolated from blood [36].
Similarly, B-cell survival in the synovium is dependent
on IL-6 and CXCL12, which are overexpressed by RA
synovial fibroblasts [37]. The lower CXCL12 expression
in LNSCs of individuals with RA risk might reflect an
attempt to prevent autoreactive B cells from accessing
the LN and impair their survival. We also detected a
Fig. 3 Regulation of T-cell proliferation by lymph node stromal cells (LNSCs). a Flow cytometry gating strategy used to identify CD4+ and
CD8+ T-cell subsets according to CD45, CD4 and CD8 expression. Numbers adjacent to the outlined areas indicate percentages of cells in
the gated population. A representative carboxyfluorescein succinimidyl ester (CSFE) dilution plot is shown for 2 of 15 donors. b Proliferation of
CSFE-labelled CD4+ and CD8+ T cells out of 50,000 peripheral blood mononuclear cell (PBMCs) (all from one donor) activated with αCD3 and αCD28
for 96 h without LNSCs (passages 4 to 8) or co-cultured with 1250 (1:40), 5000 (1:10), 10,000 (1:5) or 25,000 LNSCs (1:2). LNSCs were cultured from
healthy donors, individuals with RA risk and patients with RA and pre-treated with interferon-γ (IFN-γ) or not. Data are presented as the percentage of
total cells found in the respective cell division (mean and SD of n = 5 donors per group; donor characteristics listed in Table 3). Upper panels show
CD4+ T-cell data; lower panels show data of CD8+ T cells displayed co-cultured together with LNSCs of respective donor groups. Differences between
T cell with or without LNSCs were assessed using two-way analysis of variance ANOVA. * P < 0.050, ** P < 0.010, *** P < 0.001, **** P < 0.0001 c Nitric
oxide (NO) production in co-culture supernatants was measured after 96 h of co-culture using Griess reagent. Mean and SD of 10 donors (healthy,
n = 5; individuals with RA risk, n = 3; patients with RA, n = 2) are shown. Differences between conditions were assessed using two-way ANOVA.
* P < 0.050, ** P < 0.010. FSC-A Forward scatter area, FSC-W Forward scatter width, SSC-A Side scatter area, SSC-W Side scatter width
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lower induction of CCL19 and CXCL13 after stimulation
with TNF-α plus lymphotoxin α1β2 in LNSCs derived
from patients with RA. Overall, these data suggest that
LNSCs of individuals with RA-specific systemic auto-
immunity display an altered chemokine profile, which
may lead to disturbed trafficking of lymphocytes within
the LN. Future studies are needed to confirm this and to
investigate the mechanism by which chemokine production
is disturbed in autoimmune LNSCs.
Next to lymphocyte trafficking and survival, LNSCs
play a crucial role in regulating adaptive immune
responses. LNSCs prevent extensive T-cell proliferation
and thereby dampen immune responses through the
release of NO in a tightly regulated and contact-dependent
manner [20, 32, 33]. Our results diverge from murine
studies where low numbers of LNSCs already lead to full
inhibition and NO plays a crucial role [20, 32, 33].
We observed incomplete suppression when an LNSC/
T-cell ratio of 1:2 was used and found that proliferation
was even increased in LNSC/T-cell ratios of 1:5 and 1:10.
Even though NO levels are higher in an LNSC/T cell ratio
of 1:2, no differences were observed between donor
groups. Therefore, the altered suppressive effect observed
in RA LNSCs at the ratio of 1:2 is probably not dependent
on changes in NO production. Likewise, the expression of
IL-7, measured at P2 under homeostatic conditions that
might drive T-cell proliferation, was not differentially
expressed between donor groups or correlated with T-cell
proliferation (data not shown) [38]. Even though IFN-γ
signalling on LNSCs is crucial for NO production,
exogenous IFN-γ alone increases only NOS2, the gene
encoding inducible nitric oxidase synthase, but it fails to
increase NO or nitrite in culture medium [32]. Further-
more, Transwell experiments show that LNSC-T-cell
contact is needed to induce NO production and conse-
quently T-cell suppression [20, 32, 33]. Taken together,
this points towards additional components in this pathway
derived from intimate cell contact to constrain T-cell
proliferation, but future research is needed to formally
prove this contact dependency in human co-cultures.
Furthermore, in contrast to murine studies, which mostly
use sorted and autologous cells derived from T-cell recep-
tor (TCR) transgenic mice, we used an allogeneic co-
culture system. Missing TCR-major histocompatibility
complex (TCR-MHC) interaction might diminish close
cell-cell contact, or mismatched TCR-MHC might
additionally trigger T-cell proliferation [39]. However, our
observations in healthy LNSCs are in line with data
derived from mesenchymal stem cells (MSCs). In mice as
well as in humans, using an allogeneic system containing
MSCs and T cells, suppression of T-cell proliferation was
observed only when relatively high numbers of MSCs
were used, whereas relatively low numbers of MSCs
supported T-cell proliferation [40, 41]. Furthermore, co-
culture of allogeneic T cells with human MSCs in MSC/T-
cell ratios of 1:4 and 1:40 increased the numbers of
FoxP3-expressing cells [40], and maintenance of regula-
tory T cells by LNSCs has also been observed in mice [17].
It will be interesting to investigate in future experiments
whether human LNSCs also play a role in maintenance of
regulatory T cells and whether this process is disturbed in
LNSCs from patients with RA. However, these expe-
riments are highly challenging, because for human studies,
knowledge is lacking on well-defined self-antigens expressed
by human LNSCs and the availability of corresponding
autoreactive human Tcells.
The suppression of T cells in low LNSC/T-cell ratios
(1:2) and the immunostimulatory effect in higher ratios
(1:5 and 1:10) was seen mostly in LNSCs from healthy
individuals. In this study, we show, for the first time to
our knowledge, that this bipolar behaviour depending on
LNSC/T-cell ratio is less maintained in LNSCs derived
from patients with RA. It is tempting to speculate that
reduced inhibition of T cells might result in less inhibition
Table 3 Demographic data of study subjects used in co-culture experiments
Healthy control subjects (n = 5) Individuals with RA risk (n = 5) Patients with early RAa (n = 5)
Passages P4–P8 P4–P8 P4–P8
Female sex, n (%) 3 (60) 3 (60) 4 (80)
Median age, years (IQR) 28 (24–33) 50 (28–57) 47 (35–57)
IgM-RF-positive, n (%) 0 (0) 0 (0) 4 (80)
IgM-RF level, kU/L, median (IQR) – 3 (1–15.5) 437 (159–2210)
ACPA-positive, n (%) 0 (0) 5 (100) 5 (100)
ACPA level, kAU/L, median (IQR) – 75 (45–112.5) 328 (61–1969)
IgM-RF and ACPA both positive, n (%) 0 (0) 0 (0) 4 (80)
DAS28, median (IQR) – – 5.3 (3.2–6.8)
CRP, mg/L, median (IQR) 0.4 (0.3–2.7) 1.6 (0.7–2) 4.4 (1.3–19.8)
Abbreviations: ACPA anti-citrullinated protein antibodies, kAU/L kilo arbitrary Unit/L, CRP C-reactive protein, DAS28 disease activity score in 28 joints, IgM-RF
immunoglobulin M-rheumatoid factor, kU/L kilo Unit/L, RA rheumatoid arthritis
a Patients with early RA: naïve for disease-modifying anti-rheumatic drugs and biologics with a disease duration (defined by arthritis in any joint) less than 1 year
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of self-reactive T cells and that reduced proliferation or
induction of regulatory T cells leads to loss of tolerance.
This and the cellular mechanism behind the potential
exhausted state and aberrant function of RA LNSCs
remain to be determined in future studies.
Conclusions
Overall, we developed, for the first time to our knowledge,
an experimental model to study the role of human LNSCs
during the earliest phases of RA. Our exploratory study
shows differences between the LN microenvironment of
individuals with RA risk, patients with RA and healthy
control subjects. To study in detail their immuno-
regulatory function, in vitro expansion of LNSCs is
required. Because it is difficult to obtain LN biopsies from
a large cohort of individuals with RA risk and patients
with RA, and because the culture of human LNSCs is very
time-consuming owing to their slow growth, the number
of donors analysed in this study is relatively low. Also,
because of the high inter-individual variation in podo-
planin expression, the contribution of different LNSC
subsets to the findings reported here remains to be further
explored. The translation from in vitro results to in vivo
relevance should be demonstrated by using mouse models
or through targeted intervention studies in patients.
However, using this in vitro model, we can start delineating
the role of human LNSCs in T-cell-mediated B-cell
responses during the earliest phases of RA, which
ultimately may lead to the identification of innovative
targets for immunomodulation.
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Additional file 1: Figure S1. Gene expression levels over passages. The
expression levels of VCAM-1, ICAM-1, IL-7 and PDPN (podoplanin) in LNSCs
obtained from different passages was assessed by qPCR. Relative
quantity (RQ) of 15 donors (n = 5 per donor group) is displayed.
Figure S2. Correlation between podoplanin and IL-7 mRNA at P2.
The expression levels of PDPN (podoplanin) and IL-7 were assessed by qPCR
in passage 2 LNSCs (n = 61; donor characteristics in Table 1) and showed a
positive correlation, which was not observed for other genes measured in
these cells. Relative quantity (RQ) values were analysed by Spearman’s
correlation test. **** P < 0.0001. Figure S3. Induction of genes characteristic
for LNSCs. The expression levels of VCAM-1, ICAM-1, IL-7 and PDPN
(podoplanin) was assessed by qPCR in LNSCs (passages 4 to 8) after
stimulation with TNF-α and lymphotoxin α1β2 for 4 h and 24 h.
Mean fold induction (FI) and SD of n = 5 per donor group are shown
(donor characteristics in Table 2). The dotted line represents a fold
induction of 1. Figure S4. Correlation between podoplanin and ICAM-1
induction. The upregulated mRNA levels of PDPN and ICAM-1 upon
stimulation with TNF-α and lymphotoxin α1β2 showed a strong positive
correlation, which was not observed for VCAM-1 and IL-7. Fold induction
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Table S1. Primers used in this study. (DOCX 248 kb)
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